G1 Therapeutics Gets $12.5M Series A To Advance Chemo-Protectant Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
Based on research from the University of North Carolina and seeded by Hatteras Venture Partners, the start-up is developing cyclin-dependent kinase (CDK) 4/6 inhibitors for use in protecting the bone marrow of cancer patients receiving chemotherapy. The funding should bring the biotech through IND filing and into Phase I work.